- Email: [email protected]
ELEVATED PLASMA GALECTIN-3 IS ASSOCIATED WITH A HIGHER RISK OF CARDIOVASCULAR MORTALITY: A META-ANALYSIS
1309 JACC April 5, 2016 Volume 67, Issue 13
Heart Failure and Cardiomyopathies ELEVATED PLASMA GALECTIN-3 IS ASSOCIATED WITH A HIGHER RISK OF CARDIOVASCULAR MORTALITY: A META-ANALYSIS Poster Contributions Poster Area, South Hall A1 Saturday, April 02, 2016, 10:00 a.m.-10:45 a.m. Session Title: Predicting the Future: Biomarkers, Risk Scores, Exercise, and HF Outcomes Abstract Category: 26. Heart Failure and Cardiomyopathies: Clinical Presentation Number: 1102-053 Authors: Tasnim F. Imran, Njambi Mathenge, Frank Wang, Hyun Shin, Bernard Kim, Jacob Joseph, J. Michael Gaziano, Luc Djousse, Brigham and Women’s Hospital, Boston, MA, USA, Rutgers New Jersey Medical School, Newark, NJ, USA
Background: Galectin-3 is an emerging biomarker involved in myocardial fibrosis, inflammation, and immune response. Objective: We sought to examine the relation of galectin-3 with cardiovascular (CVD) mortality and incident heart failure.
Methods: Pubmed, EMBASE, and Cochrane Library were searched from January 2010 to October 2015 using the key terms “galectin-3,” “cardiovascular mortality,” and “heart failure.” Two reviewers independently extracted data and assessed risk of bias. Hazard ratios computed from regression models that adjusted for age, sex, race, BMI, smoking, hypertension, hyperlipidemia, diabetes, and natriuretic peptides were included.
Results: A total of 30,135 participants from 10 studies met criteria for analysis. The mean age was 60.7 +-10 years and 48% were women. Follow-up duration ranged from 1 to 15 years. Using a fixed effects meta-analysis, we found a HR of 1.25, 95% CI:1.17-1.34 for CVD mortality, 1.18, 95% CI:1.10-1.27 for incident heart failure, and 1.23, 95% CI:1.14-1.32 for all-cause mortality for each 1 SD increase in galectin-3 level, p=0.001. In a subgroup analysis of CVD mortality, the HR was 1.82, 95% CI:1.52-2.17 for patients with heart failure, and 1.18, 95% CI:1.09-1.27 for the general population, p=0.001. Conclusions: Elevated galectin-3 level is associated with a higher risk of CVD mortality in patients with heart failure, and to a lesser degree, in the general population also. It may add prognostic value beyond that provided by traditional CVD risk factors.
Heart Failure and Cardiomyopathies ELEVATED PLASMA GALECTIN-3 IS ASSOCIATED WITH A HIGHER RISK OF CARDIOVASCULAR MORTALITY: A META-ANALYSIS Poster Contributions Poster Area, South Hall A1 Saturday, April 02, 2016, 10:00 a.m.-10:45 a.m. Session Title: Predicting the Future: Biomarkers, Risk Scores, Exercise, and HF Outcomes Abstract Category: 26. Heart Failure and Cardiomyopathies: Clinical Presentation Number: 1102-053 Authors: Tasnim F. Imran, Njambi Mathenge, Frank Wang, Hyun Shin, Bernard Kim, Jacob Joseph, J. Michael Gaziano, Luc Djousse, Brigham and Women’s Hospital, Boston, MA, USA, Rutgers New Jersey Medical School, Newark, NJ, USA
Background: Galectin-3 is an emerging biomarker involved in myocardial fibrosis, inflammation, and immune response. Objective: We sought to examine the relation of galectin-3 with cardiovascular (CVD) mortality and incident heart failure.
Methods: Pubmed, EMBASE, and Cochrane Library were searched from January 2010 to October 2015 using the key terms “galectin-3,” “cardiovascular mortality,” and “heart failure.” Two reviewers independently extracted data and assessed risk of bias. Hazard ratios computed from regression models that adjusted for age, sex, race, BMI, smoking, hypertension, hyperlipidemia, diabetes, and natriuretic peptides were included.
Results: A total of 30,135 participants from 10 studies met criteria for analysis. The mean age was 60.7 +-10 years and 48% were women. Follow-up duration ranged from 1 to 15 years. Using a fixed effects meta-analysis, we found a HR of 1.25, 95% CI:1.17-1.34 for CVD mortality, 1.18, 95% CI:1.10-1.27 for incident heart failure, and 1.23, 95% CI:1.14-1.32 for all-cause mortality for each 1 SD increase in galectin-3 level, p=0.001. In a subgroup analysis of CVD mortality, the HR was 1.82, 95% CI:1.52-2.17 for patients with heart failure, and 1.18, 95% CI:1.09-1.27 for the general population, p=0.001. Conclusions: Elevated galectin-3 level is associated with a higher risk of CVD mortality in patients with heart failure, and to a lesser degree, in the general population also. It may add prognostic value beyond that provided by traditional CVD risk factors.